Leerink Partners Downgrades Fulcrum Therapeutics to Market Perform, Lowers Price Target to $4

Benzinga Newsdesk www.benzinga.com Negative 94.7%

Neg 94.7% Neu 0% Pos 0%

Leerink Partners analyst Joseph Schwartz downgrades Fulcrum Therapeutics (NASDAQ:FULC) from Outperform to Market Perform and lowers the price target from $24 to $4.